Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Caladrius Biosciences stock

Learn how to easily invest in Caladrius Biosciences stock.

Caladrius Biosciences Inc is a biotechnology business based in the US. Caladrius Biosciences shares (CLBS) are listed on the NASDAQ and all prices are listed in US Dollars. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Caladrius Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLBS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Caladrius Biosciences stock price (NASDAQ: CLBS)

Use our graph to track the performance of CLBS stocks over time.

Caladrius Biosciences shares at a glance

Information last updated 2022-09-18.
Latest market close$4.77
52-week range$0.40 - $9.75
50-day moving average $7.69
200-day moving average $9.49
Wall St. target price$4.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.39

Buy Caladrius Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Caladrius Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Caladrius Biosciences price performance over time

Historical closes compared with the close of $4.77 from 2022-09-22

1 week (2022-09-14) 1,018.67%
1 month (2022-08-22) 817.31%
3 months (2022-06-24) 853.43%
6 months (2022-03-24) 511.54%
1 year (2021-09-24) 290.98%
2 years (2020-09-24) 187.35%
3 years (2019-09-24) 76.67%
5 years (2017-09-22) 25.53%

Caladrius Biosciences financials

Gross profit TTM $0
Return on assets TTM -17.45%
Return on equity TTM -26.31%
Profit margin 0%
Book value $1.36
Market capitalisation $25.8 million

TTM: trailing 12 months

Caladrius Biosciences share dividends

We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.

Have Caladrius Biosciences's shares ever split?

Caladrius Biosciences's shares were split on a 1:15 basis on 15 September 2022. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.

Caladrius Biosciences share price volatility

Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $0.4 up to $9.75. A popular way to gauge a stock's volatility is its "beta".

CLBS.US volatility(beta: 0.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 0.9133. This would suggest that Caladrius Biosciences's shares are less volatile than average (for this exchange).

Caladrius Biosciences overview

Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.

Frequently asked questions

What percentage of Caladrius Biosciences is owned by insiders or institutions?
Currently 2.853% of Caladrius Biosciences shares are held by insiders and 19.495% by institutions.
How many people work for Caladrius Biosciences?
Latest data suggests 27 work at Caladrius Biosciences.
When does the fiscal year end for Caladrius Biosciences?
Caladrius Biosciences's fiscal year ends in December.
Where is Caladrius Biosciences based?
Caladrius Biosciences's address is: 110 Allen Road, Basking Ridge, NJ, United States, 07920
What is Caladrius Biosciences's ISIN number?
Caladrius Biosciences's international securities identification number is: US1280582032
What is Caladrius Biosciences's CUSIP number?
Caladrius Biosciences's Committee on Uniform Securities Identification Procedures number is: 128058104

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site